Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The P5 Partnership Starts First Phase III HIV Vaccine Study

Executive Summary

The P5 public-private-partnership that includes Sanofi and GlaxoSmithKline has started a pivotal Phase II/III study of a two-vaccine approach to HIV infection prevention, that could be the final nail in the coffin for HIV-AIDS if it works or yet another unwelcome victory for the virus if it doesn’t.

Advertisement

Related Content

It's A Start: Experimental HIV Vaccine Regimen Cuts Disease Risk By A Third In Thai Volunteers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel